<DOC>
	<DOCNO>NCT01700192</DOCNO>
	<brief_summary>The purpose study assess efficacy safety MK-8237 ( SCH 900237 ) treatment House Dust Mite ( HDM ) -Induced Allergic Rhinitis/Rhinoconjunctivitis ( AR/ARC ) child adult . The primary hypothesis study administration MK-8237 , compare placebo , result significant reduction average total combined rhinitis score ( TCRS ) .</brief_summary>
	<brief_title>Efficacy Safety Study SCH 900237/MK-8237 Children Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis ( P05607 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>History AR/ARC house dust 1 year duration ( without asthma ) If female childbearing potential , negative urine pregnancy test Screening agrees remain abstinent use ( partner use ) acceptable method birth control within project duration study Able read , understand complete questionnaire diary Clinically relevant history symptomatic ARC cause animal dander , mold and/or cockroach ( e.g . present home , job , daycare , etc . ) perennial allergen History symptomatic seasonal ARC and/or asthma due allergen participant sensitize regularly expose Nasal condition could confound efficacy safety assessment ( e.g. , nasal polyposis ) Received immunosuppressive treatment within 3 month prior screen Unstable severe asthma , experience lifethreatening asthma attack occurrence clinical deterioration asthma result emergency treatment , hospitalization due asthma , treatment systemic corticosteroid ( allow shortacting beta agonist [ SABAs ] ) time within 3 month prior screen Asthma require highdose inhale corticosteroid ( ICS ) within 6 month prior screen History anaphylaxis cardiorespiratory symptom prior immunotherapy , unknown cause inhalant allergen History chronic urticaria and/or angioedema within 2 year prior screen History chronic sinusitis 2 year prior screen Pregnant , breastfeeding , expect conceive within project duration study Previous immunotherapy treatment HDM allergen 1 month within 5 year prior screen Previous exposure MK8237 Receiving ongoing treatment specific immunotherapy screen Known history allergy , hypersensitivity intolerance investigational medicinal product ( except D. pteronyssinus and/or D. farinae ) , rescue medication selfinjectable epinephrine Unable meet medication washout requirement prior screen Unable unwilling comply use selfinjectable epinephrine Business personal relationship investigational site personnel Sponsor directly involve conduct study Likely travel extend period time efficacy assessment period Participating different investigational study site study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>